SGEN:NSD-Seagen Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 178.47

Change

+0.74 (+0.42)%

Market Cap

USD 33.01B

Volume

1.39M

Avg Analyst Target

USD 163.39 (-8.45%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


SGEN Stock Forecast & Price:
Based on the Seagen Inc stock forecasts from 13 analysts, the average analyst target price for Seagen Inc is USD 163.39 over the next 12 months. Seagen Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Seagen Inc is Slightly Bullish , which is based on 7 positive signals and 5 negative signals. At the last closing, Seagen Inc’s stock price was USD 178.47. Seagen Inc’s stock price has changed by +4.98% over the past week, +26.23% over the past month and +12.54% over the last year.

About Seagen Inc (SGEN:NSD)

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-c ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-06-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

-11.15 (-3.88%)

USD74.82B 30.88 20.19
REGN Regeneron Pharmaceuticals Inc

-7.98 (-1.32%)

USD67.28B 8.71 6.35
MRNA Moderna Inc

-3.17 (-2.18%)

USD57.82B 4.27 2.57
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

-3.89 (-2.71%)

USD32.57B 2.40 1.28
RPRX Royalty Pharma Plc

-0.27 (-0.63%)

USD29.12B 31.56 15.41
GMAB Genmab AS

-0.95 (-2.93%)

USD21.17B 63.61 5.25
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ARGX argenx NV ADR

-9.00 (-2.41%)

USD19.77B N/A N/A
BGNE BeiGene Ltd

-6.24 (-3.64%)

USD18.38B N/A N/A

ETFs Containing SGEN

Symbol Name Weight Mer Price(Change) Market Cap
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-2.26 (-4.44%)

USD0.10B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+1.20 (+4.66%)

USD0.01B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

-1.08 (-3.19%)

USD0.05B
EDGE:CA Evolve Innovation Index F.. 0.00 % 0.55 %

-0.34 (-1.13%)

USD0.07B
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

-1.06 (-3.54%)

USD0.19B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.07 (-1.27%)

USD0.41B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.02 (-0.43%)

USD0.46B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.08 (-1.43%)

USD0.41B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.02 (-0.46%)

USD0.46B
BMED BlackRock Future Health E.. 0.00 % 0.85 %

-0.41 (-1.81%)

N/A
OUFH:XETRA Ossiam US ESG Low Carbon .. 0.00 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.19 %

-0.45 (-2.34%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.44% 94% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.44% 94% A 96% A
Trailing 12 Months  
Capital Gain 12.54% 95% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.54% 95% A 92% A-
Trailing 5 Years  
Capital Gain 235.15% 90% A- 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 235.15% 90% A- 92% A-
Average Annual (5 Year Horizon)  
Capital Gain 35.86% 77% C+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.86% 77% C+ 85% B
Risk Return Profile  
Volatility (Standard Deviation) 47.24% 60% D- 31% F
Risk Adjusted Return 75.91% 98% A+ 93% A
Market Capitalization 33.01B 99% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 55.02 17% F 18% F
Price/Book Ratio 10.44 8% F 7% F
Price / Cash Flow Ratio -66.15 97% A+ 88% B+
EV/EBITDA 44.86 6% F 13% F
Management Effectiveness  
Return on Equity -21.47% 84% B 35% F
Return on Invested Capital -20.78% 82% B- 32% F
Return on Assets -11.45% 85% B 29% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.44 75% C 58% F
Short Percent 2.41% 69% D+ 56% F
Beta 0.84 76% C 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector